Tau Protein Aggregation Kinetics, Seed-Competent Species Identification, and Inhibition by Small-Molecule Stabilizers of the Tau R3 Microtubule-Binding Domain

This study investigates tau R3 domain aggregation nucleation kinetics, seed-competent oligomer characterization, and small-molecule stabilizer inhibition of tau fibrillization in vitro within the context of neurobiochemistry and Alzheimer's disease drug discovery, an area of growing scientific importance given its implications for tau aggregation inhibitor lead optimization, seed-competent species biomarker development, and clinical trial target selection for tauopathy disease modification. Using thioflavin T fluorescence aggregation kinetics, transmission electron microscopy, dynamic light scattering, and cell-based seeding assay with tau biosensor cells, we examine heparin promoting electrostatic beta-sheet nucleation of tau R3 domain, with seed-competent oligomers forming prior to mature fibrils and being uniquely inhibited by small molecules that stabilize monomeric microtubule-bound tau conformation in 72 aggregation conditions (4 tau concentrations x 3 heparin ratios x 6 inhibitor conditions) with n=8 technical replicates; seeding assay in tau biosensor HEK293 cells drawn from in vitro aggregation at 37 C, 900 rpm shaking in 384-well ThT fluorescence kinetics reader with TEM and DLS characterization at selected timepoints. Results indicate that seed-competent tau oligomers detected at 24-48 hours precede fibril ThT signal by 48-72 hours; BB14 reduces nucleation rate constant kn by 84.2% and seed competency by 78.4% at 10 uM versus 42% fibril reduction, suggesting preferential oligomer stabilization (p < 0.001), with BB14 reduces kn by 84.2% and seed competency by 78.4% at 10 uM as the primary quantitative benchmark. Concordance between primary and confirmatory measurement approaches exceeded 93%, validating the analytical framework. These findings contribute empirically to neurobiochemistry and Alzheimer's disease drug discovery and carry actionable implications for the design of programs and policies targeting tau aggregation inhibitor lead optimization, seed-competent species biomarker development, and clinical trial target selection for tauopathy disease modification.